Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 25257237.
- Also identified by DOI 10.1016/j.arth.2014.08.022.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
TKA and THA are associated with blood transfusion and risk for postoperative venothromboembolism (VTE). Reports show that tranexamic acid (TA) may be safe to use in high-risk orthopedic patients, but further data are needed to substantiate its use. All patients who underwent primary or revision TKA or THA in a five year period were retrospectively identified. In 13,262 elective TKA or THA procedures, neither the odds of VTE (OR=0.98; 95% CI 0.67-1.45; P=0.939) or adjusted odds of death (OR=0.26; 95% CI 0.04-1.80; P=0.171) were significant with TA administration. The major findings of this large, single center, retrospective cohort study show the odds of postoperative VTE and 30-day mortality were unchanged with TA administration.
Medical subject headings
- Antifibrinolytic Agents
- Arthroplasty, Replacement, Hip
- Arthroplasty, Replacement, Knee
- Tranexamic Acid
- Venous Thromboembolism
Anatomy
- hip
- knee